Company News

Latest News

Polaris Group Announced the Acquisition of Genovior Biotech, Initiating Dual- Engine Growth
2023/12/22-TAIPEI, Taiwan and SAN DIEGO, Calif., Dec 21- Polaris Group (TWSE: 6550) announced that its...
Read more »
Polaris Group Initiates Phase 3 Trial: First Patient Successfully Dosed with ADI-PEG 20/Placebo plus Gemcitabine and Docetaxel for Difficult-to-Treat Leiomyosarcoma (LMS)
TAIPEI, Taiwan and SAN DIEGO, Calif., Nov 30 – Polaris Group (The Company, TWSE:6550), today announced...
Read more »
Polaris Group Announces First Patient Successfully Dosed with ADI-PEG 20/Placebo in Phase 2a Non-Alcoholic Steatohepatitis (NASH) Study
TAIPEI, Taiwan and SAN DIEGO, Calif., November 29— Polaris Group (The Company, TWSE:6550), today announced...
Read more »
Polaris Group Initiates Rolling Submission of Biologic License Application (BLA) for ADI-PEG 20 with U.S. FDA to Treat Malignant Pleural Mesothelioma
TAIPEI, Taiwan and SAN DIEGO, Calif., Nov 17, 2023 – Polaris Group (The Company, TWSE:6550), today announced...
Read more »
Global Coalition for Adaptive Research and Polaris Group Announce Commencement of ADI-PEG 20 in GBM AGILE Trial
LARKSPUR, Calif.--(BUSINESS WIRE)--Global Coalition for Adaptive Research (LARKSPUR, CA) and Polaris...
Read more »
Polaris Group Appoints Ken Chang, Ph.D., as Chief Strategy Officer and Hugh Yu, Ph.D., as Chief Operating Officer
TAIPEI, Taiwan and SAN DIEGO, Calif., June 13, 2023 — Polaris Group (TWSE: 6550), a multinational biopharmaceutical...
Read more »
1 2 3 4 5 6
Scroll to Top
This site is registered on wpml.org as a development site.